{
    "name": "abaloparatide",
    "comment": "Rx",
    "other_names": [
        "Tymlos"
    ],
    "classes": [
        "Parathyroid Hormone Analogs"
    ],
    "source": "https://reference.medscape.com/drug/tymlos-abaloparatide-1000129",
    "pregnancy": {
        "common": [
            "Not indicated for females of reproductive potential"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not indicated for females of reproductive potential"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of systemic hypersensitivity to drug or components of product formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause orthostatic hypotension, typically within 4 hr after injection; associated symptoms may include dizziness, palpitations, tachycardia, or nausea; advise patients to sit or lie down for first several doses if necessary; administer where patient can sit or lie down if necessary",
                "May cause hypercalcemia; not recommended with preexisting hypercalcemia or in patients who have an underlying hypercalcemic disorder (eg, primary hyperparathyroidism) because of the possibility of exacerbating hypercalcemia",
                "May cause hypercalciuria; unknown whether the drug may exacerbate urolithiasis in patients with active or a history of urolithiasis; if active urolithiasis or preexisting hypercalciuria is suspected, consider measuring urinary calcium excretion"
            ],
            "specific": [
                {
                    "type": "Osteosarcoma",
                    "description": [
                        "Dose-dependent increase in incidence of osteosarcoma in rats observed; unknown whether it will occur in humans",
                        "Osteosarcoma reported in post-marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans",
                        "There are limited data assessing the risk of osteosarcoma beyond 2 years of this drug and/or use of a PTH-analog; therapy >2 years not recommended",
                        "Avoid use in the following patients",
                        "Open epiphyses (pediatric and young adult patients) (not approved in pediatric patients)",
                        "Metabolic bone diseases other than osteoporosis, including Pagetâ€™s disease of the bone",
                        "Bone metastases or a history of skeletal malignancies",
                        "Prior external beam or implant radiation therapy involving the skeleton",
                        "Hereditary disorders predisposing to osteosarcoma"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site redness",
            "percent": "58"
        },
        {
            "name": "Hypercalciuria",
            "percent": "11"
        },
        {
            "name": "Injection site edema",
            "percent": "11"
        },
        {
            "name": "Injection site erythema",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "8"
        },
        {
            "name": "Palpitations",
            "percent": "5"
        },
        {
            "name": "Orthostatic hypotension",
            "percent": "4"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "3"
        },
        {
            "name": "Hypercalcemia",
            "percent": "3"
        },
        {
            "name": "Vertigo",
            "percent": "2"
        },
        {
            "name": "Tachycardia",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "9"
        },
        {
            "name": "Arthralgia",
            "percent": "7"
        },
        {
            "name": "Injection site swelling",
            "percent": "7"
        },
        {
            "name": "Increased serum uric acid",
            "percent": "7"
        },
        {
            "name": "Injection site pain",
            "percent": "6"
        },
        {
            "name": "Orthostatic hypotension",
            "percent": "6"
        },
        {
            "name": "Contusion",
            "percent": "3"
        },
        {
            "name": "Abdominal distention",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Hypercalcemia",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "2"
        },
        {
            "name": "Bone pain",
            "percent": "2"
        },
        {
            "name": "Urolithiases",
            "percent": "2"
        }
    ]
}